Printer Friendly

Bruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2008.

BILLERICA, Mass. -- Bruker Corporation (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: BRKR BRKR Breaker ):

Bruker Corporation (NASDAQ: BRKR) today reported financial results for the fourth quarter and year ended December 31, 2008.

Reminder: On February 26, 2008, Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use.  closed its acquisition of the Bruker BioSpin Group, and renamed itself Bruker Corporation. Under US GAAP GAAP

See: Generally Accepted Accounting Principles


See generally accepted accounting principles (GAAP).
, this transaction is accounted for as an acquisition of businesses under common control, and as a result all one-time transaction costs Transaction Costs

Costs incurred when buying or selling securities. These include brokers' commissions and spreads (the difference between the price the dealer paid for a security and the price they can sell it).
 are expensed in the period in which they are incurred, rather than being added to goodwill. In addition, expenses incurred subsequent to the consummation of the acquisition, such as interest expenses incurred on acquisition related debt, are not reflected in the financial results of periods prior to the date of the acquisition, as they typically would be in pro-forma financials in acquisitions of unrelated parties. After the closing of the transaction all historical financial statements are required to be restated by combining the historical consolidated financial statements Consolidated Financial Statements

The combined financial statements of a parent company and its subsidiaries.

Because consolidated financial statements present an aggregated look at the financial position of a parent and its subsidiaries, they enable you to gauge
 of Bruker BioSciences Corporation with those of the Bruker BioSpin Group. Accordingly, the financial results for the three and twelve months ended December 31, 2008 and 2007, included within this release, represent the combined historical consolidated financial statements of Bruker BioSciences Corporation with those of the Bruker BioSpin Group.

Financial Results

In the fourth quarter of 2008, revenue was $315.2 million, compared to revenue of $344.8 in the fourth quarter of 2007. Excluding the effects of foreign currency translation, fourth quarter revenue decreased by 3% year-over-year. Sequentially, revenues in the fourth quarter of 2008 increased by 30%, compared to revenue of $242.1 million in the third quarter of 2008. For the year 2008, revenue increased by 7% to $1,107.1 million, compared to revenue of $1,032.4 million for the year 2007. Excluding the effects of foreign currency translation, full year 2008 revenue increased by 3% year-over-year.

GAAP operating income Operating Income

The profit realized from a business' own operations.

This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit.
 in the fourth quarter of 2008 was $48.9 million, compared to $66.4 million in the fourth quarter of 2007. For the year 2008, GAAP operating income was $108.2 million, compared to $137.7 million for the year 2007. Including the adjustments in the attached reconciliation, non-GAAP operating income in the fourth quarter of 2008 was $52.6 million, compared to $74.0 million in the fourth quarter of 2007. For the year 2008, non-GAAP operating income was $121.2 million, compared to $147.3 million in 2007.

GAAP net income for the fourth quarter of 2008 was $26.2 million, or $0.16 per diluted share, compared to $40.3 million, or $0.24 per diluted share, in the fourth quarter of 2007. For the year 2008, GAAP net income was $64.9 million, or $0.39 per diluted share, compared to $98.9 million, or $0.60 per diluted share, in the year 2007. Including the adjustments in the attached reconciliation, non-GAAP net income for the fourth quarter of 2008 was $30.4 million, or $0.18 per diluted share, compared to $47.7 million, or $0.29 per diluted share, in the fourth quarter of 2007. For the year 2008, non-GAAP net income was $77.9 million, or $0.47 per diluted share, compared to $107.9 million, or $0.66 per diluted share, in 2007.

Cash flow from operations Cash flow from operations

A firm's net cash inflow resulting directly from its regular operations (disregarding extraordinary items such as the sale of fixed assets or transaction costs associated with issuing securities), calculated as the sum of net income plus noncash expenses
 for the full year 2008 was $105.5 million, compared to $120.9 million in 2007. Free cash flow, defined as operating cash flow Operating cash flow

Earnings before depreciation minus taxes. Measures the cash generated from operations, not counting capital spending or working capital requirements.
 less capital expenditures, was $58.1 million during 2008, compared to $93.9 million during 2007. Capital expenditures for the year 2008 were $47.4 million, which was approximately $20 million higher than in 2007 due to the expansion of two manufacturing locations in 2008. During the year 2008, the Company repaid $187.0 million of the debt incurred to finance the Bruker BioSpin Group acquisition in February 2008. As of December 31, 2008, Bruker had cash and cash equivalents of $167.7 million, and net debt of $56.1 million.

Comment and Outlook

Frank Laukien, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented: "Our fourth quarter was again our strongest quarter of the year. In the fourth quarter of 2008, we had strong new order bookings and we ended the year 2008 with a healthy backlog. However, in 2008 our margins were well below our goals, and we have put aggressive cost-cutting initiatives in place, which include voluntary top-management salary decreases for 2009, selected staff reductions, hiring and salary freezes for 2009, and cut-backs in discretionary spending. In addition, we continue to drive numerous gross margin improvement projects, from which we expect to benefit in 2009 and beyond."

Dr. Laukien continued with an outlook for the year 2009: "This year offers significant challenges due to the deepening global recession and uncertain outlook. Bruker is relatively well positioned to deal with these challenges, as we have an exceptionally strong technology, IP and product portfolio and broad international diversification International diversification

The attempt to reduce risk by investing in more than one nation. By diversifying across nations whose economic cycles are not perfectly correlated, investors can typically reduce the variability of their returns.
. Bruker also derives more than 60% of its revenue from universities, medical schools, as well as other non-profit and government customers, who tend to be less sensitive to economic conditions. Some of our demand drivers are even counter-cyclical, and a few of our customers have already begun to benefit from counter-cyclical supplementary budgets and various national stimulus packages."

Bruker's CFO See Chief Financial Officer.  Bill Knight William George (Bill) Knight (born October 24 1947) is a former senior executive and Member of Parliament (MP) in the Canadian House of Commons.

A teacher by profession, Knight was first elected as a New Democratic Party MP in a 1971 by-election and was re-elected in 1972.
 added: "Financially, we expect to continue to have a strong balance sheet, positive operating and free cash flow, ample borrowing capacity, and clear opportunities to improve our margins, balance sheet metrics and cash flow generation. On this solid financial foundation, we will invest further in our future, even during 2009, with additional market development in attractive applied markets, including food and consumer safety, pharma PAT, forensics See computer forensics.  and toxicology, as well as in clinical research and IVD (Interactive VideoDisc) See interactive video. , homeland security Noun 1. Homeland Security - the federal department that administers all matters relating to homeland security
Department of Homeland Security

executive department - a federal department in the executive branch of the government of the United States
 and explosives detection, and advanced superconducting magnets and devices. Leveraging our strong technology base into these near-term additional growth and margin opportunities makes strategic sense for Bruker, and we intend to emerge from this recession as an even stronger company."

Mr. Knight continued: "Given the apparent further deterioration of the global economy in January and February 2009, and the uncertainty of the timing and effect of various international stimulus efforts, forecasting for the full year 2009 is extremely difficult. We have nevertheless established internal financial goals for ourselves in 2009, and intend to drive Bruker towards:

* a currency-adjusted low single digit percentage decline in revenue or flat revenue,

* an improvement in non-GAAP operating margin Operating Margin

A ratio used to measure a company's pricing strategy and operating efficiency.

Calculated by:
 and EPS (Encapsulated PostScript) A PostScript file format used to transfer a graphic image between applications and platforms. EPS files contain PostScript code as well as an optional preview image in TIFF, WMF, PICT or EPSI, the latter being an ASCII-only format. , and

* a positive net cash position before the end of 2009."


In addition to the financial measures prepared in accordance with generally accepted accounting principles The standard accounting rules, regulations, and procedures used by companies in maintaining their financial records.

Generally accepted accounting principles (GAAP) provide companies and accountants with a consistent set of guidelines that cover both broad accounting
 (GAAP), we use the measures of non-GAAP operating income, non-GAAP net income and non-GAAP EPS, which exclude certain items such as one-time restructuring charges, acquisition-related charges, non-cash stock-based compensation, and other special charges. We exclude these items because they are outside of our normal operations Generally and collectively, the broad functions that a combatant commander undertakes when assigned responsibility for a given geographic or functional area. Except as otherwise qualified in certain unified command plan paragraphs that relate to particular commands, "normal operations" of  and, in certain cases, are difficult to forecast accurately for future periods. We believe that such non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company's performance, especially when comparing such results to previous periods or forecasts. However, the non-GAAP financial measures included in this press release are not meant to be a better presentation or a substitute for results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying tables. Specifically:

* Reconciliation of Operating Income

* Reconciliations of Net Income and Earnings Per Share


Bruker Corporation will host an operator-assisted earnings conference call at 8:30 a.m. Eastern Time on Tuesday, March 3, 2009. To listen to the webcast, investors can go to and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days. Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or +1-617-847-3007 outside the US and Canada. Investors should refer to the Bruker Earnings Call. A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or +1-617-801-6888 outside the US and Canada, and then entering replay pass code 34501830. For more information, please visit


Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending capital spending

Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years.
 and government funding policies, changes in governmental regulations, intellectual property rights, litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.

When a person begins a civil lawsuit, the person enters into a process called litigation.
, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K Form 10-K

A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.

Form 10-K

See 10-K.
 for the year ended December 31, 2007, our most recent quarterly reports on Form 10-Q Form 10-Q

See 10-Q.
 and our current reports on Form 8-K Form 8-K

The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock.

Form 8-K

See 8-K.
. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

(a) "GAAP" (Reported) results were determined in accordance with United States Generally Accepted Accounting Principles (GAAP).

(b) Results in 2008 and 2007 include charges associated with the acquisition of the Bruker BioSpin Group. Under US GAAP, this transaction was accounted for as an acquisition of businesses under common control, and as a result, all one-time transaction costs, including investment banking, legal and accounting fees, were expensed as incurred.

(c) Results in 2008 and 2007 include charges associated with non-cash stock-based compensation.

(d) Results in 2008 include restructuring charges, primarily associated with severance obligations due to headcount reductions.

(e) Result in 2008 included in restructuring charges were one time additional German and Swiss income taxes of $1.7 million associated with the liquidation of a tax ineffective legal entity within the Bruker BioSpin segment.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Financial report
Date:Mar 3, 2009
Previous Article:BG Medicine Appoints Doug White as Executive Vice President & General Manager, Diagnostics.
Next Article:OSI Systems Receives $27 Million Order for Electronic Sub-Assemblies.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters